logo
Plus   Neg
Share
Email

Petrofac Expects To Deliver Net Profit Growth In 2012 Of At Least 15%

Petrofac Ltd. (PFC.L,POFCY.PK,POFCF.PK) issued interim management statement for the period from January 1, 2012 to May 11, 2012.

The company stated that continuing operations are performing in-line with expectations and added that it expects to deliver net profit growth in 2012 of at least 15%.

Petrofac noted that it started the year well and are making good operational progress across its portfolio of projects. Besides, the company continues to bid actively in its core markets and believe that its differentiated and competitive offering positions it well to capitalise on the large number of opportunities Petrofac sees.

The group's backlog at the end of April 2012 stood at $9.6 billion, comprising $7.9 billion from Engineering, Construction, Operations & Maintenance and $1.7 billion from Integrated Energy Services. Net cash balances were lower at the end of April 2012 at $1.0 billion.

Ayman Asfari, group chief executive, commented, "We remain confident that we will deliver net profit growth in 2012 of at least 15%, in line with our previous guidance, and remain on course to achieve our medium-term target of more than doubling our recurring 2010 Group earnings by 2015."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT